Crossmark

Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide

Crossref DOI link: https://doi.org/10.1007/s00392-018-1283-6

Published Online: 2018-05-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shiraishi, Yasuyuki

Nagai, Toshiyuki

Kohsaka, Shun

Goda, Ayumi

Nagatomo, Yuji

Mizuno, Atsushi

Kohno, Takashi

Rigby, Alan

Fukuda, Keiichi

Yoshikawa, Tsutomu

Clark, Andrew L.

Cleland, John G. F.
Funding

Funding for this research was provided by:

KAKENHI (21790751)

Butterfield Awards for UK-Japan collaboration in Medicine & Health
License Information

Text and Data Mining valid from 2018-05-21
More Information

Article History

Received: 9 November 2017

Accepted: 16 May 2018

First Online: 21 May 2018

Compliance with ethical standards

:

: Dr. Kohsaka received an unrestricted research grant for the Department of Cardiology, Keio University School of Medicine from Bayer Pharmaceutical Co., Ltd and Daiichi Sankyo Co. Ltd. Dr. Nagai is supported by grants from the Daiichi Sankyo Foundation of Life Science and the Mochida Memorial Foundation for Medical and Pharmaceutical Research. Dr. Cleland acknowledges support from Amgen, Novartis, Medtronic, and Servier. Other authors have no conflicts of interest to disclose. There are no patents, products in development, or marketed products to declare.